Latest & greatest articles for autism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on autism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on autism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Autism

Autism is a neurodevelopmental disorder (a type of mental disorder) characterised by difficult social interaction, impaired communication (both verbal and non-verbal), and restricted and repetitive behaviours. It forms part of the broader autism spectrum disorder (ASD), a range of similar conditions, including Asperger syndrome.

Autism is a condition that begins from early childhood and is often suspected and diagnosed by ages 1-3. It is a lifelong disability that affects how people interact with others.

Autism causes and treatment

There have been many misconceptions as to what causes autism in the past such as the MMR vaccine and diet. Extensive research and clinical trials have concluded that none of these factors cause autism or ASD. However, the real cause is little understood but research is starting to unpick potential factors such as genetics, pollution and other environmental factors. A current favoured idea is that genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors.

The exact cause of autism spectrum disorder is unknown, however research into the disorder suggest that it is caused by several genetic and environmental factors. Genes inherited from a child’s parents can make them more vulnerable to developing autism, some researchers suggest that the disorder will only develop when triggered by environmental factors. Read more in clinical papers on autism.

Autism can be managed with a combination of prescribed medicines and behavioural treatment, depending on the severity of the disorder. Read about clinical trials and medical advancements for the treatment of autism on Trip.

Hot topics in Trip

Users of Trip frequently look at topics around adolescents, therapies, behaviour and screening. They also explore such topics as omega-3 fatty acids, SSRIs and aripiprazole. All these topics, and more, can be easily searched for within Trip.

Top results for autism

1. Cognitive Behavioral Treatments for Anxiety in Children With Autism Spectrum Disorder: A Randomized Clinical Trial

Cognitive Behavioral Treatments for Anxiety in Children With Autism Spectrum Disorder: A Randomized Clinical Trial Cognitive Behavioral Treatments for Anxiety in Children With Autism Spectrum Disorder: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions 2019 Nov 22 [Online ahead of print] Cognitive Behavioral Treatments for Anxiety in Children With Autism Spectrum Disorder: A Randomized Clinical Trial , , , , , , , Affiliations Expand Affiliations 1 Department of Education, University of California, Los Angeles, Los Angeles. 2 Department

2020 EvidenceUpdates

2. Effect of a Computer-Based Decision Support Intervention on Autism Spectrum Disorder Screening in Pediatric Primary Care Clinics: A Cluster Randomized Clinical Trial Full Text available with Trip Pro

Effect of a Computer-Based Decision Support Intervention on Autism Spectrum Disorder Screening in Pediatric Primary Care Clinics: A Cluster Randomized Clinical Trial Effect of a Computer-Based Decision Support Intervention on Autism Spectrum Disorder Screening in Pediatric Primary Care Clinics: A Cluster Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed (...) collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions , 2 (12), e1917676 2019 Dec 2 Effect of a Computer-Based Decision Support Intervention on Autism Spectrum Disorder Screening in Pediatric Primary Care Clinics: A Cluster Randomized Clinical

2020 EvidenceUpdates

3. Provision for people with a known or suspected learning disability, autism or both

Provision for people with a known or suspected learning disability, autism or both NHS England » Provision for people with a known or suspected learning disability, autism or both Search Search Menu Provision for people with a known or suspected learning disability, autism or both Document first published: 22 January 2020 Page updated: 22 January 2020 Topic: Publication type: Document PDF 432 KB 22 pages

2020 NHS England

4. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder 1 1 Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and 2 adolescents with autism spectrum disorder 3 4 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 5 American Academy of Neurology 6 7 Ashura Williams Buckley, MD, 1 Deborah Hirtz, MD, 2 Maryam Oskoui, MD, 3 Melissa J. 8 Armstrong, MD, MSc, 4 Anshu Batra (...) . Division of Developmental Medicine, Boston Children’s Hospital, Boston, MA 24 2 7. Departments of Pediatrics and Psychiatry, The Ohio State University College of 1 Medicine, Columbus 2 8. Duke Center for Autism and Brain Development, Duke Institute for Brain Sciences, and 3 Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 4 Durham, NC 5 9. Northern Michigan Neurology, Traverse City 6 10. Department of Child and Behavioral Sciences, Johns Hopkins University

2020 American Academy of Neurology

5. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis Full Text available with Trip Pro

Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis Dietary interventions such as restrictive diets or supplements are common treatments for young people with autism spectrum disorder (ASD). Evidence for the efficacy of these interventions is still controversial.To assess the efficacy of specific dietary interventions on symptoms, functions, and clinical domains in subjects with ASD by using a meta-analytic approach.Ovid Medline, PsycINFO, Embase databases.We selected placebo

2019 EvidenceUpdates

6. Physical activity for persons with ADHD or autism

. 23672 6. 1 OR 2 OR 3 OR 4 OR 5 40896 7. "Autistic Disorder"/ or "Autism Spectrum Disorder"/ 26189 8. (Autism or Autistic* or "ASD" or "Autism spectrum disorder*").ti,ab,kw. 50587 9. 7 OR 8 53333 10. 6 OR 9 90701 Intervention: 11. Exercise/ 101551 12. ("Physical" adj6 ("Activit*" or "therap*" or "exercise" or “training”)).ti,ab,kw. 155219 13. (exercise* or physiotherapy or sport*).ti,ab. 345492 14. 11 OR 12 OR 13 466786 Limits: 15. (((comprehensive* or integrative or systematic*) adj3 (bibliographic (...) found Population: 1. [mh “Attention Deficit and Disruptive Behavior Disorders”] 2809 2. [mh “Attention Deficit Disorder with Hyperactivity”] 2482 3. (“Attention Deficit Disorder*”:ab,ti) 3751 4. ("Attention deficit*":ab,ti NEAR hyper*:ab,ti) 3529 5. (“adhd”:ti,ab,kw OR “addh”:ti,ab) 4168 6. 1 OR 2 OR 3 OR 4 OR 5 5506 7. [mh "Autistic Disorder"] 867 8. [mh "Autism Spectrum Disorder"] 1211 9. ("Autism" or Autist* or "ASD" OR "Autism spectrum*"):ti,ab 3467 10. 7 OR 8 OR 9 3523 11. 6 OR 10 8787

2019 Swedish Council on Technology Assessement

7. Use of electronic screen media prior to dental appointment can help to reduce anxiety in patients with Autism Spectrum Disorder

Use of electronic screen media prior to dental appointment can help to reduce anxiety in patients with Autism Spectrum Disorder UTCAT3390, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Use of electronic screen media prior to dental appointment can help to reduce anxiety in patients with Autism Spectrum Disorder Clinical Question Can use of electronic screen media prior to dental appointment help reduce anxiety (...) in patients with Autism Spectrum Disorder? Clinical Bottom Line For children with Autism Spectrum Disorder (ASD), certain types of electronic screen media may be helpful to reduce anxiety during dental appointments. This randomized controlled study based on 80 subjects found that electronic screen media could be used to reduce anxiety in children with ASD. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Isong

2019 UTHSCSA Dental School CAT Library

8. Early detection for autism spectrum disorder in young children

Early detection for autism spectrum disorder in young children Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder, characterized by impairments in social communication, repetitive, restricted patterns of behaviour, and unusual sensory sensitivities or interests. ASD significantly impacts the lives of children and their families. Currently, the estimated prevalence of ASD is 1 in 66 Canadians aged 5 to 17 years. General paediatricians, family physicians, and other health (...) signs of ASD—an important step toward an accurate diagnosis and comprehensive needs assessment for intervention planning. Keywords: Autism spectrum disorder; Developmental surveillance; Early identification; Screening

2019 Canadian Paediatric Society

9. Post-diagnostic management and follow-up care for autism spectrum disorder

Post-diagnostic management and follow-up care for autism spectrum disorder Paediatricians and other primary care providers are well positioned to provide or coordinate ongoing medical and psychosocial care and support services for children with autism spectrum disorder (ASD). This statement provides recommendations and information on a range of interventions and resources, to help paediatric care providers optimize care for children with ASD and support their families. The management of ASD (...) includes treating medical and psychiatric co-morbidities, behavioural and developmental interventions, and providing supportive social care services to enhance quality of life for affected children and families. Keywords: Autism spectrum disorder; Behavioural interventions; Complementary and alternative medicine; Developmental interventions; Pharmacological management

2019 Canadian Paediatric Society

10. Standards of diagnostic assessment for autism spectrum disorder

Standards of diagnostic assessment for autism spectrum disorder The rising prevalence of autism spectrum disorder (ASD) has created a need to expand ASD diagnostic capacity by community-based paediatricians and other primary care providers. Although evidence suggests that some children can be definitively diagnosed by 2 years of age, many are not diagnosed until 4 to 5 years of age. Most clinical guidelines recommend multidisciplinary team involvement in the ASD diagnostic process. Although (...) on referral for a comprehensive needs assessment both for treatment and intervention planning, using a flexible, multilevel approach. Keywords: Autism spectrum disorder; Diagnostic evaluation; Intervention planning

2019 Canadian Paediatric Society

11. Fecal Microbiota Transplantation for Autism: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fecal Microbiota Transplantation for Autism: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fecal Microbiota Transplantation for Autism: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fecal Microbiota Transplantation for Autism: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fecal Microbiota Transplantation for Autism: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: June 13, 2019 Project Number (...) : RB1353-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of fecal microbiota transplantation for the treatment of individuals with autism spectrum disorder? What is the cost-effectiveness of fecal microbiota transplantation for the treatment of individuals with autism spectrum disorder? What are the evidence-based guidelines regarding the use of fecal microbiota transplantation for the treatment

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome 1 Published 9 September 2019 1 SMC2168 melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) Flynn Pharma Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep

2019 Scottish Medicines Consortium

13. Psychotropic drugs and people with learning disabilities or autism

Psychotropic drugs and people with learning disabilities or autism Psychotropic drugs and people with learning disabilities or autism: executive summary - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Psychotropic drugs and people with learning disabilities or autism: executive summary Published 22 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open (...) Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning

2019 Public Health England

14. WITHDRAWN: Gluten- and casein-free diets for autistic spectrum disorder. Full Text available with Trip Pro

WITHDRAWN: Gluten- and casein-free diets for autistic spectrum disorder. It has been suggested that peptides from gluten and casein may have a role in the origins of autism and that the physiology and psychology of autism might be explained by excessive opioid activity linked to these peptides. Research has reported abnormal levels of peptides in the urine and cerebrospinal fluid of people with autism.To determine the efficacy of gluten and/or casein free diets as an intervention to improve (...) programmes which eliminated gluten, casein or both gluten and casein from the diets of individuals diagnosed with an autistic spectrum disorder.Abstracts of studies identified in searches of electronic databases were assessed to determine inclusion by two independent authors The included trials did not share common outcome measures and therefore no meta-analysis was possible. Data are presented in narrative form.Two small RCTs were identified (n = 35). No meta-analysis was possible. There were only three

2019 Cochrane

15. Prenatal and infant exposure to ambient pesticides and autism spectrum disorder in children: population based case-control study. Full Text available with Trip Pro

Prenatal and infant exposure to ambient pesticides and autism spectrum disorder in children: population based case-control study. To examine associations between early developmental exposure to ambient pesticides and autism spectrum disorder.Population based case-control study.California's main agricultural region, Central Valley, using 1998-2010 birth data from the Office of Vital Statistics.2961 individuals with a diagnosis of autism spectrum disorder based on the Diagnostic and Statistical (...) and autism spectrum disorder (with or without intellectual disabilities) in offspring, adjusting for confounders.Risk of autism spectrum disorder was associated with prenatal exposure to glyphosate (odds ratio 1.16, 95% confidence interval 1.06 to 1.27), chlorpyrifos (1.13, 1.05 to 1.23), diazinon (1.11, 1.01 to 1.21), malathion (1.11, 1.01 to 1.22), avermectin (1.12, 1.04 to 1.22), and permethrin (1.10, 1.01 to 1.20). For autism spectrum disorder with intellectual disability, estimated odds ratios were

2019 BMJ

16. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Full Text available with Trip Pro

Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause concern and challenge vaccine uptake.To evaluate whether the MMR vaccine increases the risk for autism in children, subgroups of children, or time periods after vaccination.Nationwide cohort study.Denmark.657 461 children born in Denmark from 1999 through 31 December 2010, with follow-up from 1 year of age and through 31 (...) August 2013.Danish population registries were used to link information on MMR vaccination, autism diagnoses, other childhood vaccines, sibling history of autism, and autism risk factors to children in the cohort. Survival analysis of the time to autism diagnosis with Cox proportional hazards regression was used to estimate hazard ratios of autism according to MMR vaccination status, with adjustment for age, birth year, sex, other childhood vaccines, sibling history of autism, and autism risk factors

2019 Annals of Internal Medicine

17. Autism in adults

), especially when under stress or expressing emotion. If two or more of the above categories of behaviour are present, offer referral to an autism team if available (or if not, to a psychiatrist) for a comprehensive (diagnostic, needs, and risks) assessment for ASD. Provide verbal and written information on ASD. For example: The National Autistic Society website ( ) has information on available before diagnosis of ASD, the , , available , and what to do . Basis for recommendation Basis for recommendation (...) for people with ASD and how to decisions about benefits; services; and other (such as blue badges, bus passes, and Disabled Facilities Grants). The National Autistic Society Autism Helpline (0808 800 4104, ) — provides impartial, confidential information, advice, and support for people with ASD and their family, partners, and/or carers. It is available from 10am–4pm on Monday–Thursday, and 9am–3pm on Fridays. The NHS website ( ) — has a guide on , which is also available in an for people with a learning

2019 NICE Clinical Knowledge Summaries

18. Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism Full Text available with Trip Pro

Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism Children and adolescents with autism spectrum disorder (ASD) are a highly medicated group. Few studies have examined the neuropsychiatric profile and patterns of psychotropic medication use among adults with ASD.To describe and compare the neuropsychiatric profile and psychotropic medication use in a cohort of adults with ASD (...) and non-autistic controls.Baseline data from a survey-based, longitudinal study of adults with ASD in Australia. Participants were 188 adults with ASD and 115 controls aged 25-80 years.ASD was associated with increased odds of psychotropic medication use even when controlling for the presence of any neurological or psychiatric disorder. There were no corresponding indications for 14.4% of psychotropic medications prescribed to adults with ASD.This study found substantial psychotropic prescribing

2018 BJPsych open

19. Communication interventions for autism spectrum disorder in minimally verbal children. Full Text available with Trip Pro

Communication interventions for autism spectrum disorder in minimally verbal children. Autism spectrum disorder (ASD) has an estimated prevalence of around 1.7% of the population. People with ASD often also have language difficulties, and about 25% to 30% of children with ASD either fail to develop functional language or are minimally verbal. The ability to communicate effectively is an essential life skill, and difficulties with communication can have a range of adverse outcomes, including (...) of Child Health and Human Development, the MIND Institute Research Program and a Professional Staff Congress-City University of New York grant. The PECS study included 84 minimally verbal participants (73 boys) aged 4 to 11 years who had a formal diagnosis of ASD and who were not using PECS beyond phase 1 at baseline. All children attended autism-specific classes or units, and most classes had a child to adult ratio of 2:1. Teachers and parents received PECS training (two-day workshop). PECS

2018 Cochrane

20. Stem cell transplantation as treatment for children with autism

Stem cell transplantation as treatment for children with autism Stem cell transplantation as treatment for children with autism We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Stem cell transplantation as treatment for children with autism Share: Reading time approx. 1 minute Stem cell transplantations are performed to treat certain forms of cancer (...) but also to treat some other rarer disorders. Today stem cell clinics advertise stem cell transplantation as a treatment to disorders like autism at high costs. There are however doubts about the efficacy and safety of these treatments. Question Which scientific studies have investigated stem cell transplantation as treatment for children with autism? Identified literature Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and Observations from a Placebo-Controlled, Crossover Study

2018 Swedish Council on Technology Assessement